Compare stocks

Cellectis S.A. is a biotechnology company specializing in gene-editing for cancer immunotherapy. It focuses on developing allogeneic CAR-T cell products designed to address various hematological and solid tumors using its proprietary TALEN gene editing technology. Founded in 1999, Cellectis is headquartered in Paris, France, and operates facilities in both France and the United States, enhancing its global research and development capabilities. The company's strategic positioning is characterized by its focus on creating off-the-shelf CAR-T therapies, aiming to reduce the complexity and cost associated with personalized CAR-T treatments, thereby broadening accessibility to advanced cancer therapies.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.